In an outpatient receiving trastuzumab emtansine (Kadcyla) who reports a yeast infection, what is the appropriate management?

Management of Yeast Infection in Patient on Kadcyla

Treat the yeast infection with standard antifungal therapy—there are no specific contraindications or dose modifications of Kadcyla required for a simple yeast infection. The Kadcyla (trastuzumab emtansine) FDA label does not list fungal infections as a concern requiring dose modification or treatment interruption 1.

Treatment Approach

For Vulvovaginal Candidiasis (Most Likely Scenario)

First, confirm the diagnosis clinically by assessing for typical symptoms: pruritus, irritation, vaginal soreness, dysuria, and dyspareunia, often with thick white discharge. If possible, obtain a wet-mount preparation with 10% potassium hydroxide to demonstrate yeast or hyphae and confirm normal pH (4.0-4.5) 2.

For uncomplicated infection (90% of cases):

• Single-dose fluconazole 150 mg orally is the recommended first-line treatment 2
• Alternative: Any topical antifungal agent (no superiority of one over another) 2
• Both achieve >90% response rates 2

For severe or complicated infection:

• Fluconazole 150 mg every 72 hours for 2-3 total doses 2
• Or topical agents for 5-7 days 2

For Oral Candidiasis (If Applicable)

For mild disease:

• Clotrimazole troches 10 mg 5 times daily for 7-14 days 2
• Or nystatin suspension 4-6 mL 4 times daily for 7-14 days 2

For moderate to severe disease:

• Oral fluconazole 100-200 mg daily for 7-14 days 2

Key Considerations for Kadcyla Patients

No Kadcyla Modifications Required

The FDA label for Kadcyla specifies dose modifications only for: hepatotoxicity, thrombocytopenia, left ventricular dysfunction, pulmonary toxicity, and peripheral neuropathy 1. Fungal infections are not listed as requiring any treatment interruption or dose adjustment.

Monitor for Immunosuppression

While patients on Kadcyla are not typically considered severely immunocompromised like those with hematologic malignancies 3, 4, cancer treatment can increase susceptibility to infections. If the yeast infection is:

• Recurrent (≥4 episodes/year): Consider maintenance fluconazole 150 mg weekly for 6 months after initial 10-14 day induction therapy 2
• Refractory to standard azoles: Consider non-albicans species (particularly C. glabrata) and use alternative agents like intravaginal boric acid 600 mg daily for 14 days 2

Continue Kadcyla as Scheduled

Do not delay or interrupt Kadcyla administration for a simple yeast infection. The treatment schedule should be maintained at 3.6 mg/kg every 3 weeks 1. Only hold Kadcyla for the specific toxicities outlined in the FDA label.

Common Pitfalls to Avoid

• Do not assume all vaginal symptoms are yeast infections—confirm diagnosis when possible, as symptoms are nonspecific 2
• Do not unnecessarily interrupt cancer therapy—yeast infections are manageable without stopping Kadcyla
• Do not overlook C. glabrata if the patient fails initial fluconazole therapy, as this species has reduced azole susceptibility 2
• Do not prescribe prophylactic antifungals unless the patient develops recurrent infections (≥4/year) 2